Doppler imaging measurements are repeatable in OAG patients

Article

The repeatability of colour Doppler imaging (CDI) measurements in open-angle glaucoma (OAG) patients has been confirmed by a study published in Journal of Glaucoma.

The repeatability of colour Doppler imaging (CDI) measurements in open-angle glaucoma (OAG) patients has been confirmed by a study published in Journal of Glaucoma.

Dr Rita Ehrlich et al., Department of Ophthalmology, Indiana School of Medicine, Indianapolis, Indiana, USA, conducted a cross-sectional, observational study on 116 OAG patients involved in the Indianapolis Glaucoma Progression Study. At the same time of day to baseline measurements were recorded 1 to 2 weeks apart on all patients. CDi measurements of retrobulbar blood flow velocities and Pourcelot's vascular resistance index (RI) were analysed.

Intraclass correlation coefficient (ICC) between the 2 baseline measurements was determined. Other measurements included the calculation of RI and peak systolic and end diastolic blood flow velocities (PSV/EDV) in the ophthalmic (OA), central retinal (CRA), and nasal and temporal short posterior ciliary arteries (N/TPCA).

Measurements in the OA were all above 0.82 in the intraobserver ICC for the PSV, EDV and RI. Measurements in the CRA were both above 0.8 in the intraobserver ICC PSV and RI. EDV in the CRA was found to be 0.64.

Intraobserver ICC in the N/TPCA for the PSV, EDV, and RI measurements varied between 0.71 and 0.88. It was generally similar to the intraobsever ICC for the OA and the CRA, but lower than 0.7 in the EDV and RI.

If performed on OAG patients within 2 weeks the blood flow velocities and calculated vascular resistance of the OA, CRA and PCA are repeatable.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.